Epidermal growth factor receptor inhibitors in colorectal cancer treatment: What’s new?

摘要: Colorectal cancer constitutes one of the most common malignancies and second leading cause death from in western world representing million new cases half a deaths annually worldwide. The treatment patients with metastatic colon comprises different regimens chemotherapeutic compounds (fluoropyrimidines, irinotecan oxaliplatin) targeted therapies. Interestingly, recent trials that attempt to expose all five-drug classes irinotecan, oxaliplatin, bevacizumab cetuximab) achieve an overall survival well over 2 years. In this review we will focus on main epidermal growth factor receptor inhibitors demonstrating clinical benefit for colorectal mainly cetuximab, panitumumab, erlotinib gefitinib. We also describe briefly molecular steps lie beneath them or mechanisms are reported resistance response.